mepsevii
ultragenyx germany gmbh - vestronidase alfa - mukopolysakkaridoosi vii - entsyymit - mepsevii on indisoitu ei-neurologisia ilmenemismuotoja, joilla on diagnosoitu mukopolysakkaridoosi vii (mps vii; sly-oireyhtymä).
enteroporc coli ac
ceva santé animale - clostridium perfringens type c, beta1 toxoid / clostridium perfringens, type a, alpha toxoid / clostridium perfringens, type a, beta2 toxoid / escherichia coli, fimbrial adhesin f4ab / escherichia coli, fimbrial adhesin f4ac / escherichia coli, fimbrial adhesin f5 / escherichia coli, fimbrial adhesin f6 - immunologicals for suidae, inactivated bacterial vaccines (including mycoplasma, toxoid and chlamydia) escherichia + clostridium - siat - for the passive immunisation of progeny by active immunisation of pregnant sows and gilts to reduce:- clinical signs (severe diarrhoea) and mortality caused by escherichia coli strains expressing the fimbrial adhesins f4ab, f4ac, f5 and f6- clinical signs (diarrhoea during the first days of life) associated with clostridium perfringens type a expressing alpha and beta 2 toxins- clinical signs and mortality associated with haemorrhagic and necrotising enteritis caused by clostridium perfringens type c expressing beta1 toxin.
ultifend nd ibd
ceva-phylaxia veterinary biologicals co. ltd - turkey herpes virus, strain rhvt/nd/ibd, expressing the fusion protein of newcastle disease virus and the vp2 protein of infectious bursal disease virus, live recombinant - immunologiset lääkkeet - embryonated chicken eggs; chicken - for the active immunisation of one-day-old chicks or 18-day-old chicken embryonated eggs to reduce mortality, clinical signs and lesions caused by newcastle disease virus (ndv) and to reduce virus shedding; to reduce mortality, clinical signs and bursa lesions caused by very virulent infectious bursal disease virus (ibdv); to reduce mortality, clinical signs and lesions caused by classical marek’s disease virus (mdv).
voraxaze
serb sas - glucarpidase - metabolic side effects of drugs and substances - kaikki muut terapeuttiset tuotteet - voraxaze is indicated to reduce toxic plasma methotrexate concentration in adults and children (aged 28 days and older) with delayed methotrexate elimination or at risk of methotrexate toxicity.
strattera 5 mg kapseli, kova
eli lilly finland oy ab - atomoxetini hydrochloridum - kapseli, kova - 5 mg - atomoksetiini
strattera 4 mg/ml oraaliliuos
eli lilly finland oy ab - atomoxetini hydrochloridum - oraaliliuos - 4 mg/ml - atomoksetiini
clarithromycin accord 250 mg tabletti, kalvopäällysteinen
accord healthcare b.v. accord healthcare b.v. - clarithromycinum - tabletti, kalvopäällysteinen - 250 mg - klaritromysiini
clarithromycin accord 500 mg tabletti, kalvopäällysteinen
accord healthcare b.v. accord healthcare b.v. - clarithromycinum - tabletti, kalvopäällysteinen - 500 mg - klaritromysiini
firmagon
ferring pharmaceuticals a/s - degareliksia - prostatiset kasvaimet - endokriinihoito - firmagon is a gonadotrophin releasing hormone (gnrh) antagonist indicated:- for treatment of adult male patients with advanced hormone-dependent prostate cancer. - for treatment of high-risk localised and locally advanced hormone dependent prostate cancer in combination with radiotherapy. - as neo-adjuvant treatment prior to radiotherapy in patients with high-risk localised or locally advanced hormone dependent prostate cancer.
libmeldy
orchard therapeutics (netherlands) bv - atidarsagene autotemcel - leukodystrophy, metachromatic - muut hermoston huumeet - libmeldy is indicated for the treatment of metachromatic leukodystrophy (mld) characterized by biallelic mutations in the arysulfatase a (arsa) gene leading to a reduction of the arsa enzymatic activity:in children with late infantile or early juvenile forms, without clinical manifestations of the disease,in children with the early juvenile form, with early clinical manifestations of the disease, who still have the ability to walk independently and before the onset of cognitive decline.